1. Home
  2. News
  3. Immutep Ltd
  4. Approval to start Efti & Bavencio trial in urothelial cancer
More Immutep Ltd news
Immutep LtdASX: IMM

Approval to start Efti & Bavencio trial in urothelial cancer

Apr 30, 2023 at 10:32 PM EDT · Issued by Immutep Ltd

Filed with ASX · Apr 30, 2023 at 10:32 PM EDT · 2 pages · English

On 6ix: 6ix.com/news/approval-to-start-efti-and-bavencio-trial-in-urothelial-cancer

Immutep Ltd on 6ix

Story so far

  • Initiation of Phase 2 Trial for Efti in Soft Tissue SarcomaApr 17, 2023
  • Expansion of INSIGHT-003 trial for Efti in 1st Line NSCLCMar 30, 2023
  • Commercial Scale in Manufacturing of Efti AchievedDec 8, 2022

Earlier from Immutep

  • Immutep to announce new TACTI-002 data at ASCO 2023Apr 26, 2023
  • Response to ASX Aware QueryApr 18, 2023
  • Initiation of Phase 2 Trial for Efti in Soft Tissue SarcomaApr 16, 2023
  • Positive Final Data in 2nd Line Metastatic NSCLC PatientsMar 31, 2023
  • Expansion of INSIGHT-003 trial for Efti in 1st Line NSCLCMar 29, 2023

Later from Immutep

  • FDA supportive of Efti registrational trial in lung cancerMay 15, 2023
  • Excellent initial Overall Survival Benefit in 1st line NSCLCMay 16, 2023
  • Promising New Data in 1st line NSCLC from INSIGHT-003 TrialMay 23, 2023
  • 1st patient dosed in AIPAC-003 ph2/3 breast cancer trialMay 24, 2023
  • Publication of Abstracts for ASCO 2023 Annual MeetingMay 25, 2023
All Immutep news releases↗

Follow Immutep into a list and get an email when it puts out news.

Follow Immutep
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer